Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» major depressive disorder
major depressive disorder
After phase 2 fail, Actinogen reports new data in bid to salvage depression drug xanamem
Fierce Biotech
Mon, 08/26/24 - 10:16 pm
Actinogen
cortisol blockers
major depressive disorder
clinical trials
xanamem
Autobahn’s road to a breakthrough depression treatment is paved with high-profile investors
Pharma Voice
Wed, 08/7/24 - 11:22 am
Autobahn Therapeutics
depression
ABX-002
major depressive disorder
Autobahn raises $100M on investor interest in neuropsych drugs
BioPharma Dive
Thu, 07/25/24 - 11:09 am
Autobahn Therapeutics
major depressive disorder
bipolar disorder
funding
ABX-002
5 Neuro Data Readouts to Watch in the Second Half of 2024
BioSpace
Mon, 07/15/24 - 11:43 am
neurology
clinical trials
Athira Pharma
fosgonimeton
Alzheimer's disease
AbbVie
Cerevel Therapeutics
emraclidine
schizophrenia
Neumora Therapeutics
major depressive disorder
navacaprant
Amylx
AMX003
Wolfram syndrome
Vigil Neuroscience
iluzanebart
Nexalin’s deep brain stimulation add-on therapy alleviates depression
Clinical Trials Arena
Thu, 06/27/24 - 09:59 pm
Nexalin
major depressive disorder
Medtech
deep brain stimulation
Intra-Cellular Therapies edges closer to FDA win for Caplyta in depression
Clinical Trials Arena
Tue, 06/18/24 - 07:52 pm
Intra-Cellular Therapies
clinical trials
major depressive disorder
Caplyta
Why Otsuka launched a digital health company
Medical Marketing and Media
Mon, 06/10/24 - 11:13 am
Otsuka
Otsuka Precision Health
Medtech
digital therapeutics
major depressive disorder
Otsuka defies digital health downturn with new company
BioPharma Dive
Thu, 05/30/24 - 11:07 am
Otsuka
Medtech
digital health
major depressive disorder
Otsuka Precision Health
J&J's depression treatment succeeds in late-stage study
Yahoo/Reuters
Wed, 05/29/24 - 11:45 am
JNJ
major depressive disorder
clinical trials
seltorexant
Gilgamesh starts subject dosing in major depressive disorder trial
Clinical Trials Arena
Thu, 05/2/24 - 11:25 am
Gilgamesh Pharmaceuticals
clinical trials
GM-1020
major depressive disorder
Neurocrine-Takeda med reduces depression severity in phase 2, though analysts ask for more data detail
Fierce Biotech
Tue, 04/23/24 - 09:42 pm
Neurocrine Biosciences
clinical trials
Takeda
major depressive disorder
Savitri
Intra-Cellular Launches 26% To Record High, Breaking Out After Depression Drug Scores Big
Investors Business Daily
Tue, 04/16/24 - 11:13 am
Intra-Cellular Therapies
Caplyta
clinical trials
major depressive disorder
Cybin CEO on FDA breakthrough designation for psychedelic drug treating MDD
Medical Marketing and Media
Mon, 04/1/24 - 11:48 am
Cybin
FDA
psychedelics
major depressive disorder
MindBio nears completion of MB22001 trial for depression
Clinical Trials Arena
Wed, 01/31/24 - 11:46 am
MindBio Therapeutics
clinical trials
LSD
MB22001
major depressive disorder
6 Neuro Data Readouts to Watch in the First Half of 2024
BioSpace
Mon, 01/22/24 - 11:53 am
neurodegenerative disease
clinical trials
ALS
major depressive disorder
Huntington's disease
Sanofi
Denali Therapeutics
Intra-Cellular Therapies
lumateperone
Annexon Biosciences
Guillain-Barré Syndrome
ANX005
Wave Life Sciences
Praxis Precision Medicines
As J&J outlines bullish pipeline goals, neuroscience pipeline takes a starring role
Fierce Biotech
Wed, 12/6/23 - 09:15 pm
JNJ
Neuroscience
Spravato
major depressive disorder
Alto’s Neuropsychiatric Platform Scores Third Mid-Stage Win
BioSpace
Tue, 12/5/23 - 09:55 am
Alto Neuroscience
ALTO-300
major depressive disorder
clinical trials
Xenon Looks to Raise Cash for MDD Program with $300M Public Offering
BioSpace
Thu, 11/30/23 - 11:15 pm
Xenon
major depressive disorder
stock offering
Neurocrine Hit with Back-to-Back Phase II Failures in Neuropsychiatry
BioSpace
Fri, 11/10/23 - 10:14 am
Neurocrine
neuropsychiatric
clinical trials
focal onset seizures
major depressive disorder
NBI-921352
NBI-1065846
Novartis cuts depression study, nearly erasing $210M Cadent acquisition from pipeline
Fierce Biotech
Tue, 10/10/23 - 11:36 am
Novartis
Cadent Therapeutics
major depressive disorder
MIJ821
Pages
1
2
3
4
5
next ›
last »